TD Asset Management
KRYS icon

TD Asset Management’s Krystal Biotech KRYS Stock Holding History

TD Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.44M Sell
22,712
-20,606
-48% -$6.16M 0.01% 695
2026
Q1 		$11.2M Sell
43,318
-10,824
-20% -$2.88M 0.01% 620
2025
Q4 		$13.3M Buy
54,142
+9,062
+20% +$1.91M 0.01% 592
2025
Q3 		$7.96M Buy
45,080
+25,000
+125% +$3.74M 0.01% 711
2025
Q2 		$2.76M Sell
20,080
-20,188
-50% -$2.97M ﹤0.01% 870
2025
Q1 		$7.26M Sell
40,268
-3,212
-7% -$540K 0.01% 715
2024
Q4 		$6.81M Buy
43,480
+10,000
+30% +$1.77M 0.01% 727
2024
Q3 		$5.93M Sell
33,480
-24,600
-42% -$4.74M 0.01% 761
2024
Q2 		$10.7M Sell
58,080
-11,082
-16% -$1.86M 0.01% 609
2024
Q1 		$12.3M Buy
69,162
+28,200
+69% +$3.92M 0.01% 588
2023
Q4 		$5.08M Buy
40,962
+18,542
+83% +$2.06M 0.01% 765
2023
Q3 		$2.6M Buy
22,420
+6,610
+42% +$806K ﹤0.01% 885
2023
Q2 		$1.86M Buy
+15,810
New +$1.61M ﹤0.01% 982
2020
Q4 		– Sell
-15,922
Closed -$685K – 1456
2020
Q3 		$685K Sell
15,922
-8,833
-36% -$384K ﹤0.01% 1170
2020
Q2 		$1.02M Buy
24,755
+4,000
+19% +$192K ﹤0.01% 1054
2020
Q1 		$897K Sell
20,755
-5,300
-20% -$277K ﹤0.01% 1029
2019
Q4 		$1.44M Buy
26,055
+600
+2% +$29.4K ﹤0.01% 1009
2019
Q3 		$884K Buy
25,455
+5,400
+27% +$241K ﹤0.01% 1077
2019
Q2 		$808K Buy
20,055
+11,902
+146% +$389K ﹤0.01% 1092
2019
Q1 		$268K Buy
+8,153
New +$192K ﹤0.01% 1274

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TD Asset Management's KRYS Position: Q2 2026 in Review

TD Asset Management reduced its Krystal Biotech (KRYS) stake by 48% in Q2 2026, selling an estimated $6.16M and leaving 22,712 shares worth $8.44M. The position accounts for 0.01% of the portfolio, ranked #695.

TD Asset Management first reported a position in KRYS in Q1 2019 and has held it in 20 quarters since. The position peaked at $13.3M in Q4 2025. 331 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • TD Asset Management held 22,712 shares of Krystal Biotech worth $8.44M as of Q2 2026.
  • TD Asset Management sold 20,606 Krystal Biotech shares in Q2 2026, an estimated $6.16M.
  • Krystal Biotech made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #695 holding.
  • TD Asset Management first reported a position in Krystal Biotech in Q1 2019 and has held it in 20 quarters since.
  • TD Asset Management's Krystal Biotech position peaked at $13.3M in Q4 2025.
  • 331 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.